Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XCUR

XCUR - Exicure Inc Stock Price, Fair Value and News

$4.27-0.18 (-4.04%)
Market Closed

22/100

XCUR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

22/100

XCUR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$4.93

Target 3M

$5.58

Target 6M

$5.24

XCUR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XCUR Price Action

Last 7 days

-32.0%

Last 30 days

-21.9%

Last 90 days

-3.8%

Trailing 12 Months

-62.9%

XCUR RSI Chart

XCUR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XCUR Valuation

Market Cap

27.2M

Price/Earnings (Trailing)

-2.95

Price/Sales (Trailing)

50.48

EV/EBITDA

-2.53

Price/Free Cashflow

-3.06

XCUR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$4.93

Target 3M

$5.58

Target 6M

$5.24

XCUR Fundamentals

XCUR Revenue

Revenue (TTM)

500.0K

XCUR Earnings

Earnings (TTM)

-9.2M

Earnings Growth (Yr)

-123.37%

Earnings Growth (Qtr)

7.02%

XCUR Profitability

EBT Margin

-1845.80%

Return on Equity

-133.23%

Return on Assets

-60.45%

Free Cashflow Yield

-32.7%

XCUR Investor Care

Shares Dilution (1Y)

193.41%

Diluted EPS (TTM)

-3.68

XCUR Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202421.7M14.7M7.6M500.0K
20223.8M6.1M7.1M28.8M
20218.4M3.7M00
202010.5M14.9M16.8M16.6M
2019107.0K522.0K992.0K1.3M
20187.3M4.9M2.5M118.0K
20173.2M5.4M7.5M9.7M
2016001.7M1.0M
20150002.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Exicure Inc

XCUR
Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
 CEO
 WEBSITEexicuretx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Exicure Inc Frequently Asked Questions

XCUR is the stock ticker symbol of Exicure Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Exicure Inc is 27.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XCUR's fair value in chart for subscribers.

The fair value guage provides a quick view whether XCUR is over valued or under valued. Whether Exicure Inc is cheap or expensive depends on the assumptions which impact Exicure Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XCUR.

As of Wed Jan 28 2026, XCUR's PE ratio (Price to Earnings) is -2.95 and Price to Sales (PS) ratio is 50.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XCUR PE ratio will change depending on the future growth rate expectations of investors.